Saniona AB (publ) (STO:SANION)

Market Cap	2.71B
Revenue (ttm)	743.21M
Net Income (ttm)	573.47M
Shares Out	138.03M
EPS (ttm)	4.56
PE Ratio	4.30
Forward PE	8.71
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,450,837
Average Volume	1,244,917
Open	19.36
Previous Close	19.72
Day's Range	19.20 - 20.15
52-Week Range	5.41 - 20.10
Beta	1.20
RSI	71.33
Earnings Date	Nov 27, 2025

About Saniona AB

Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company’s product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy, which is in Phase 2b clinical trial for the treatment of hypothalamic ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 22
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SANION